Tech Company Financing Transactions

TP Therapeutics Funding Round

Lilly Asia Ventures, OrbiMed and SR One Capital Management participated in a $45 million Series C funding round for TP Therapeutics. The round was announced on 5/24/2017.

Transaction Overview

Company Name
TP Therapeutics
Announced On
5/24/2017
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series C
Investors

Lilly Asia Ventures (Lead Investor) (Hongbo Lu)

OrbiMed (Lead Investor) (Carl Gordon)

SR One Capital Management (Lead Investor) (Simeon George)

Cormorant Asset Management

SV Tech Ventures

Proceeds Purpose
Proceeds from the financing will be used to fund the continued development of the company's lead program, TPX-0005, for treatment of naïve and resistant patients with ALK, ROS1 or NTRK abnormal genes. The proceeds will also be used to fund the advancement of several pre-clinical pipeline projects.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10628 Science Center Dr. 225
San Diego, CA 92121
USA
Phone
(858) 926-5251
Website
www.tptherapeutics.com
Email Address
[email protected]
Overview
TP Therapeutics, Inc. is a structure-based drug design company headquartered in San Diego, California. TP is focusing on the discovery and development of precision medicines for cancer and other diseases.
Profile
TP Therapeutics LinkedIn Company Profile
Social Media
TP Therapeutics Company Twitter Account
Company News
TP Therapeutics News
Facebook
TP Therapeutics on Facebook
YouTube
TP Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Jean Cui
  Jean Cui LinkedIn Profile  Jean Cui Twitter Account  Jean Cui News  Jean Cui on Facebook
Chief Executive Officer
Athena Countouriotis
  Athena Countouriotis LinkedIn Profile  Athena Countouriotis Twitter Account  Athena Countouriotis News  Athena Countouriotis on Facebook
Co-Founder
Yishan Li
  Yishan Li LinkedIn Profile  Yishan Li Twitter Account  Yishan Li News  Yishan Li on Facebook
Vice President
Armin Graber
  Armin Graber LinkedIn Profile  Armin Graber Twitter Account  Armin Graber News  Armin Graber on Facebook
Vice President
Jeffrey Whitten
  Jeffrey Whitten LinkedIn Profile  Jeffrey Whitten Twitter Account  Jeffrey Whitten News  Jeffrey Whitten on Facebook
VP - Finance
Brian Baker
  Brian Baker LinkedIn Profile  Brian Baker Twitter Account  Brian Baker News  Brian Baker on Facebook
VP - Operations
Miriam Cruz
  Miriam Cruz LinkedIn Profile  Miriam Cruz Twitter Account  Miriam Cruz News  Miriam Cruz on Facebook
VP - Operations
Yuelie Lu
  Yuelie Lu LinkedIn Profile  Yuelie Lu Twitter Account  Yuelie Lu News  Yuelie Lu on Facebook
VP - Regulatory Affairs
John Lim
  John Lim LinkedIn Profile  John Lim Twitter Account  John Lim News  John Lim on Facebook
VP - Regulatory Affairs
Naresh Nayyar
  Naresh Nayyar LinkedIn Profile  Naresh Nayyar Twitter Account  Naresh Nayyar News  Naresh Nayyar on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/24/2017: Icebreaker Health venture capital transaction
Next: 5/24/2017: Bowery Valuation venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.